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1  | INTRODUC TION
In combination with standard interferon and pegylated interferon 
(pegIFN), ribavirin (RBV) has been shown to significantly decrease 
the risk of post- treatment viral relapse and increase rates of sus-
tained virological response (SVR) in patients with hepatitis C virus 
(HCV) infection.1,2 Despite improving the efficacy of IFN- based 
therapy, RBV is associated with haemolytic anaemia,3,4 a phenom-
enon driven by accumulation of RBV in erythrocytes and oxida-
tive damage within the red blood cells.5 RBV- associated decline in 
haemoglobin levels is dose- dependent and can be exacerbated by 
the suppressive effects of interferon on bone marrow,6 which sup-
presses compensatory reticulocytosis.7
In the current era of all- oral, IFN- free, direct- acting antivirals 
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Abstract
Background & Aims: Some individuals with hepatitis C virus infection treated with 
direct- acting antivirals require ribavirin to maximize sustained virological response rates. 
We describe the clinical management of ribavirin dosing in hepatitis C virus- infected 
patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Methods: We performed a post hoc analysis of patients receiving ombitasvir/pari-
taprevir/ritonavir and dasabuvir with ribavirin for 12 or 24 weeks in six phase 3 trials. 
Multivariate stepwise logistic regression models assessed predictors associated with 
ribavirin dose adjustments and with developing anaemia.
Results: Of 1548 patients, 100 (6.5%) modified ribavirin dose due to haemoglobin 
declines, of which 99% achieved sustained virological response at 12 weeks post- 
treatment. Median time to first ribavirin dose reduction was 37 days. Low baseline 
haemoglobin was significantly associated with an increased risk of requiring ribavirin 
dose modification (odds ratio: 0.618 [0.518, 0.738]; P < .001) and developing anaemia 
(odds ratio: 0.379 [0.243, 0.593]; P < .001).
Conclusions: Ribavirin dose reductions were infrequent, occurred early in treatment, 
and did not impact sustained virological response at 12 weeks post- treatment. Patients 
with low baseline haemoglobin should be monitored for on- treatment anaemia.
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the addition of RBV to DAA treatment regimens can result in higher 
SVR rates by reducing post- treatment viral relapse and limiting se-
lection of HCV resistance- associated variants among some difficult- 
to- cure individuals.8-10
Six phase 3 trials evaluated the all- oral DAA regimen of ombi-
tasvir (OBV, an NS5A inhibitor), paritaprevir (an NS3/4A protease 
inhibitor identified by AbbVie and Enanta, and dosed with ritonavir, 
PTV/r) and dasabuvir (DSV, a non- nucleoside NS5B RNA polymerase 
inhibitor) with or without RBV in HCV genotype (GT)1- infected pa-
tients that were either treatment naive or pegIFN experienced, with 
or without compensated cirrhosis.8,11-14 Overall, the frequency and 
clinical severity of anaemia were low across the six trials; 6.5% of 
subjects had a decrease in haemoglobin levels to <10 g/dL during 
treatment with OBV/PTV/r + DSV + RBV, and <1% had a haemoglo-
bin decrease to <8 g/dL.8,11-14
Anaemia- related adverse events can be effectively managed 
through adjustments in RBV dose. However, optimal clinical man-
agement of anaemia requires an understanding of (1) when clinically 
significant declines in haemoglobin levels are likely to occur, (2) the 
characteristics of patients that are likely to require RBV dose re-
ductions and (3) the impact of RBV dose reductions on treatment 
outcomes. This post hoc pooled analysis describes the clinical man-
agement of RBV dosing in GT1- infected patients receiving OBV/
PTV/r + DSV + RBV in six phase 3 trials.
2  | PATIENTS AND METHODS
Patients in the phase 3 SAPPHIRE- I and - II, PEARL- II, - III and - IV, 
and TURQUOISE- II studies received OBV/PTV/r (25/150/100 mg 
once daily) and DSV (250 mg twice daily) for 12 weeks (non- cirrhotic 
patients), or for either 12 or 24 weeks (cirrhotic patients). Where ad-
ministered, RBV was dosed according to body weight with a total 
daily	 dose	 of	 1000	mg	 (<75	kg)	 or	 1200	mg	 (≥75	kg).	 The	 design,	
patient characteristics, and overall efficacy and safety outcomes of 
these studies have been described previously.8,11-14
RBV dose modifications were protocol- specified for (1) patients 
without cardiac disease with a haemoglobin decline to <10 g/dL, 
or	a	haemoglobin	decline	≥4	g/dL	in	two	consecutive	visits;	 (2)	pa-
tients with cardiac disease with a haemoglobin decline to <12 g/
dL,	or	a	haemoglobin	decline	≥2	g/dL	during	4	weeks	of	treatment	
and (3) any patient with a confirmed calculated creatinine clearance 
(CrCl) <50 mL/min. RBV dose was reduced according to the local 
Prescribing Information for RBV.
The percentage of patients with first and with second RBV dose 
modifications, and the mean and median time to first and secondary 
modifications were calculated. Mean haemoglobin concentrations 
over time were plotted for patients with and without RBV dose 
modifications.
Stepwise logistic regression models (α = 0.10 to enter and to re-
main in the model) assessed predictors associated with RBV dose 
modification and predictors associated with developing anaemia. 
Among all patients, stepwise logistic regression modelled RBV dose 
modification as the dependent variable, and among the 100 patients 
with a RBV dose modification, anaemia (haemoglobin <10 g/dL) was 
modelled as the dependent variable. Independent variables in both 
regression models included age, sex, race, ethnicity, prior pegIFN/
RBV treatment experience, baseline cirrhosis status, and baseline 
values for body mass index (BMI), haemoglobin, CrCl, albumin and 
platelet count.
All patients in the studies provided written informed consent 
before any study- specific procedures were carried out. The studies 
were conducted in accordance with the International Conference on 
Harmonisation guidelines, applicable regulations and the principles 
of the Declaration of Helsinki. The study protocols were approved 
by each of the independent ethics committees (IECs) or institutional 
review boards (IRBs) at each of the participating study sites (a list of 
IECs/IRBs can be found in Table S1).
3  | RESULTS
In the six phase 3 studies, the overall rate of patients requiring a 
RBV dose modification was low. Of 1548 patients receiving RBV, 
only 100 (6.5%) reduced the RBV dose due to haemoglobin de-
clines. A total of 715 (46.2%) of these patients received an OBV/
PTV/r + DSV + RBV regimen that is recommended by the current 
(2016) guidelines of the American Association for the Study of Liver 
Diseases (AASLD).15 Five patients received erythropoietin (four pa-
tients in TURQUOISE- II and one patient in SAPPHIRE- I); none re-
ceived a blood transfusion.11,16
At first dose adjustment, the majority of patients (56/100; 56%) 
were managed with a reduction in RBV dose to 600 mg, and only 
10 patients (10/100; 10%) were reduced to 400 mg or lower. The 
Key points
• Among 1548 patients treated with ombitasvir/pari-
taprevir/ritonavir and dasabuvir with ribavirin for 12 or 
24 weeks in six phase 3 trials, ribavirin dose reductions 
due to haemoglobin declines were infrequent, occurring 
in 100 (6.5%) patients
• Ribavirin dose reductions with ombitasvir/paritaprevir/
ritonavir and dasabuvir with ribavirin occurred early in 
treatment and did not impact sustained virological re-
sponse at 12 weeks post-treatment
• Low baseline haemoglobin was significantly associated 
with an increased risk of requiring ribavirin dose modifi-
cation and developing anaemia
• Patients with low baseline haemoglobin should be moni-
tored for on-treatment anaemia with ombitasvir/pari-
taprevir/ritonavir and dasabuvir with ribavirin 
treatment
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majority (65%) of RBV dose reductions occurred within the first 
6 weeks of treatment, and the median time to first dose reduction 
was 37 days (95% CI 36.0, 44.0; Table S2).
Of the 100 patients that modified the RBV dose, 20 required a 
second RBV dose reduction. The majority (14/20; 70%) of secondary 
dose adjustments occurred within 8 weeks of starting treatment, on 
median day 48 (Table S2). Three (15%) of the 20 patients with at least 
two reductions in RBV dose had an increase in RBV dose before the 
second RBV dose reduction.
Logistic regression analyses demonstrated that low baseline 
haemoglobin level (P < .001), low CrCl rate (P < .001), older age 
(P < .001) and higher baseline BMI (P = .013) were associated with a 
significantly increased likelihood of requiring a RBV dose modifica-
tion (Table 1). Differences between these characteristics in patients 
with and without RBV dose modifications are presented in Table S2.
In patients with RBV dose reductions, mean haemoglobin declines 
were observed within 4 weeks of receiving OBV/PTV/r + DSV + RBV, 
after which haemoglobin levels plateaued until the end of treatment 
(Figure 1). The mean (±SD) maximum decline in haemoglobin level 
was	 −4.1	±	1.26	g/dL,	 compared	 with	 −2.7	±	1.19	g/dL	 in	 patients	
without RBV dose reductions. Laboratory- confirmed anaemia (hae-
moglobin <10 g/dL) was observed in 63 of the 100 patients that re-
duced the RBV dose, and haemoglobin levels declined to <8 g/dL in 
four patients. Mean haemoglobin levels returned to near baseline 
values by post- treatment week 4 (Figure 1). After RBV dose reduc-
tion, recovery of haemoglobin levels during treatment led to an in-
crease in RBV dose in 16 patients (16/100; 16%), as per the study 
protocols.
Regression analysis among the 100 patients with RBV modifi-
cations identified low baseline haemoglobin (P < .001) as the only 
factor significantly associated with developing anaemia (Table 1).
Ribavirin (RBV) dose reductions, including secondary reductions, 
did not impact the ability of patients to achieve a sustained virologi-
cal response 12 weeks post- treatment (SVR12) in the phase 3 trials. 
The SVR12 rate among patients that required a reduction in RBV 
dose was 99% (99/100); only one 64- year- old white male with an 
IL28B non- CC genotype and HCV GT1a infection without cirrhosis 
did not achieve SVR12. Furthermore, reducing the RBV dose prior 
to achieve HCV RNA below the lower limit of quantification (LLOQ; 
Odds ratio 95% CI P
Increased risk of RBV dose modification
Baseline haemoglobin level (continu-
ous, g/dL)
0.618 0.518, 0.738 <.001
Baseline CrCl (continuous, mL/s) 0.261 0.123, 0.554 <.001
Age (continuous, years) 1.06 1.02, 1.09 <.001
Baseline BMI (continuous, kg/m2) 1.08 1.02, 1.15 .013
Increased risk of anaemia (haemoglobin <10 g/dL) among patients with RBV dose modifications
Baseline haemoglobin level (continu-
ous, g/dL)
0.379 0.243, 0.593 <.001
aIndependent baseline variables that were considered in the stepwise multivariate logistic regres-
sion models were age (years), prior pegIFN/RBV experience (yes, no), sex (male, female), race (black, 
Asian, white), ethnicity (Hispanic/Latino, other), baseline cirrhosis status (yes, no), and baseline val-
ues for BMI (kg/m2), haemoglobin (g/dL), CrCl (mL/s), platelet count (109/L), albumin (g/L).
BMI, body mass index; CrCl, creatinine clearance; RBV, ribavirin.
TABLE  1 Patient characteristics 
associated with increased risk of RBV 
dose modification and anaemiaa
F IGURE  1 Mean (±SE) haemoglobin level declines in 
patients with or without a ribavirin dose reduction following 
OBV/PTV/r + DSV + RBV treatment for 12 weeks (A) or 24 weeks 
(B). The mean plot is shown across time for haemoglobin levels in 
patients that received ombitasvir/paritaprevir/r and dasabuvir plus 
ribavirin in six phase 3 trials
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25 IU/mL) did not affect response rates. All seven patients that re-
quired a dose reduction before HCV RNA <LLOQ achieved SVR12. 
The one patient who did not achieve SVR12 had HCV RNA <LLOQ at 
Study Day 15, prior to reduce RBV dose at Study Day 29.
4  | DISCUSSION
Across six phase 3 studies of OBV/PTV/r + DSV + RBV, RBV dose re-
ductions were required in only 6.5% of patients, compared with ap-
proximately 20% of patients receiving pegIFN/RBV therapy in past 
studies.1,2 Head- to- head studies have recently reported RBV dose 
reductions to be lower in patients receiving OBV/PTV/r + DSV + RBV 
compared with those receiving the first- generation protease inhibi-
tor, telaprevir, in combination with pegIFN/RBV.17
The majority of RBV dose modifications occurred early in the 
course of treatment, and successfully halted haemoglobin declines 
with only 20% of patients requiring further RBV dose decreases. 
The majority of patients were managed with a reduction in RBV 
dose to 600 mg. Moreover, reducing RBV dose prior to achieve HCV 
RNA below the LLOQ had no negative impact on achieving SVR12. 
Previous studies evaluating pegIFN/RBV therapy also concluded 
that mild to moderate RBV dose reductions do not adversely affect 
SVR rates.18,19
In the present analysis, low baseline haemoglobin levels and 
low baseline CrCl rates, as well as older age, were identified as pre-
dictive factors associated with RBV dose modifications, and these 
observations are in keeping with previously reported predictors 
of anaemia.20,21 Higher BMI was identified as a predictor in the 
presence of the other predictors although with a low odds ratio 
(OR: 1.08; P = .013). There was no significant difference in BMI 
between patients with and without RBV dose reductions (P = .396; 
Table S3).
The majority (63%) of patients that received a RBV dose modifi-
cation had declines in haemoglobin to <10 g/dL (Grade 2 anaemia); 
only 4% had declines in haemoglobin to <8 g/dL (Grade 3 anaemia). 
Across the phase 3 studies, the highest rates of anaemia occurred 
in patients with compensated cirrhosis (TURQUOISE- II),8,11-14 a pa-
tient population that typically has higher rates of HCV- treatment- 
related adverse events.22 In the recent TURQUOISE- III study, OBV/
PTV/r + DSV achieved 100% SVR12 in GT1b- infected patients with 
compensated cirrhosis, demonstrating that RBV is not required in 
these patients.23
Using multivariate logistic regression, the only significant factor 
associated with anaemia among subjects with RBV dose modifica-
tions was lower baseline haemoglobin levels. Therefore, our data 
suggest that patients with low baseline haemoglobin levels should 
be monitored most carefully for RBV- associated declines in haemo-
globin and managed through RBV dose reductions. The same princi-
ples also apply to patients with decompensated cirrhosis for whom 
current guidelines recommend the use of ribavirin, either weight- 
based or low initial dose.15,24 However, it is important to note that, 
like all protease- inhibitor- containing regimens, OBV/PTV/r + DSV 
should not be used in patients with Child- Pugh B/C cirrhosis due to 
an increased risk of hepatotoxicity.25-27
In summary, although haemoglobin decreases were more com-
mon with OBV/PTV/r + DSV + RBV than without the use of RBV 
(haemoglobin <10 g/dL did not occur in any patients receiving the 
RBV- free regimen across the six trials), significant anaemia was un-
common and was managed with RBV dose reductions alone in most 
patients, without any negative impact on SVR12.
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